Admission Date:  [**2102-8-29**]              Discharge Date:   [**2102-8-31**]  Date of Birth:  [**2043-2-21**]             Sex:   F  Service: MEDICINE  Allergies: Penicillins / Tetracycline / Cipro Cystitis / Benadryl Decongestant / Motrin / Zofran / Prochlorperazine Maleate  Attending:[**First Name3 (LF) 2297**] Chief Complaint: oxaliplatin desensitization  Major Surgical or Invasive Procedure: none  History of Present Illness: 59F with initial high risk pT3N2bMX KRAS/BRAF-WT colon cancer s/p resection [**6-/2098**] and adjuvant FOLFOX who developed metastatic recurrence [**6-/2100**] and is now s/p C15 FOLFIRI-Avastin followed by 7 cycles Cetuximab-Irinotecan who developed progressive disease and is now on third line oxaliplatin/capecitabine therapy.
Was admitted a weeek ago for oxaliplatin reaction during her C2D1 oxaliplatin infusion.
The oxaliplatin was stopped and then restarted.
Was admitted for management of oxaliplatin reaction.
She was treated with 20 mg IV dexamethasone, hydroxyzine for itching, 2 mg IV ativan, Emend, and received IVF 1L.
Since discharge she has resumed her Capecitabine 1gm [**Hospital1 **] and on [**8-22**] completed 14d on therapy.
-- From [**6-/2098**]--[**1-/2099**] she received adjuvant chemotherapy with FOLFOX which was complicated by severe neuropathy, minor PORT problems and nausea.
-- [**2099-3-12**] She had a takedown ileostomy resection of distal and proximal ileum w/ enterostomy.
This procedure was aborted d/t difficult sedation and another biopsy was not attempted.
-- [**2100-8-11**] she was seen in consultation with Dr. [**First Name4 (NamePattern1) **] [**Last Name (NamePattern1) **] and tentatively planned for colon resection, Right lobectomy, segmental liver resection, IOUS, and resection of prior ileosigmoid anastomosis on [**2100-8-27**].
-- [**2100-9-13**] PORT placed and C1D1 FOLFIRI, no avastin with cycle 1 due to recent PORT.
-- [**2100-12-6**] C4D1 FOLFIRI-Avastin -- [**2101-1-10**] C5D1 FOLFIRI-Avastin -- [**2101-2-14**]  C6D1 FOLFIRI-Avastin -- [**2101-3-9**]  CT Torso: Stable disease, no new sites -- [**2101-3-15**]  C7D1 FOLFIRI-Avastin -- [**2101-4-11**]  C8D1 FOLFIRI-Avastin -- [**2101-5-6**]  C9D1 FOLFIRI-Avastin -- [**2101-6-6**]  C10D1 FOLFIRI-Avastin -- [**2101-6-14**]  CT Torso: Stable disease, no new sites -- [**2101-7-26**]   C12D1 FOLFIRI-Avastin -- [**2101-8-22**]   C13D1 FOLFIRI-Avastin -- [**2101-9-1**]  admitted with buttock abscess, drained in ED -- [**2101-9-28**]   C14D1 FOLFIRI (Avastin Held for buttock wound) -- [**2101-10-17**]  C15D1 FOLFIRI (Avastin Held for buttock wound) -- [**2101-10-21**]  CT TORSO with significant hepatic progression -- [**2101-11-1**] C1D1 Cetuximab-Irinotecan -- [**2101-12-12**] C2D1 Cetuximab-Irinotecan -- [**1-3**] C2D22 admitted with volume depletion, [**Last Name (un) **], resolved with IVF and anti-motility agents.
-- [**2102-1-24**] C3D1 Cetuximab-Irinotecan -- [**2102-2-20**] C4D1 Cetuximab-Irinotecan (D8, D15 Irinotecan held for diarrhea, D22 ([**3-14**]) Cetuximab held for worsening rash -- [**2102-3-20**] C5D1 Cetuximab-Irinotecan -- [**2102-4-3**] C5D15 HELD for diarrhea -- [**2102-4-10**] C5D22 Irinotecan held, Cetuximab given -- [**2102-4-18**] C5D28 Cetuximab -- [**4-24**] C5D36 Cetuximab -- [**2102-5-1**] C6D1 Cetuximab-Irinotecan -- [**2102-5-23**] C7D1 Cetuximab-Irinotecan -- [**6-5**], [**6-12**] -- Chemo held for GI toxicities -- [**2102-6-14**] CT with interval progression and >20% increase in hepatic disease burden, no new disease sites, CEA rising -- [**2102-6-24**] C1D1 Capecitabine 1500mg PO BID  Other PMH: 1.
S/p CCK 9.
Stage IV Colorectal cancer as above 10.
She has a first cousin with hemachromatosis and an aunt with several gastric surgeries (not for malignancy)   Physical Exam: EXAM ON ADMISSION General: Alert, oriented, no acute distress HEENT: Sclera anicteric, MMM, oropharynx clear, EOMI, PERRL Neck: supple, JVP not elevated, no LAD CV: Regular rate and rhythm, normal S1 + S2, no murmurs, rubs, gallops Lungs: Clear to auscultation bilaterally, no wheezes, rales, ronchi.
The chemotherapy port catheter is seen with the tip in the mid SVC.
IMPRESSION:  There is no obvious break in the port catheter that can be visualized on plain film.
Brief Hospital Course: # Oxaliplatin desensitization: Followed protocol per hematology/oncology service with one to one monitoring, continuous vital signs monitoring, and premedication protocol including hydroxyzine, famotidine, montelukast, and methylprednisolone.
She received 50 mg IV diphenhydramine and 1 mg ativan in addition to a 1 liter fluid bolus, after which her heart rate improved.
# Chronic back pain: In order to better monitor vital signs, patient's home vicodin was held in favor of oxycodone for pain control.
This was attributed to chronic steroid use, as the patient denied constitutional symptoms.
Medications on Admission: CAPECITABINE [XELODA] - 500 mg tablet - 2 tablet(s) by mouth twice a day Take [**Hospital1 **] for 14days, then stop for 7days and repeat.
ICD9 Code: 153.9 DEXAMETHASONE - 4 mg tablet - 2 Tablet(s) by mouth once a day On day 2 and 3 after chemotherapy.
HYDROCODONE-ACETAMINOPHEN - 5 mg-500 mg tablet - 1 Tablet(s) by mouth Q4-6hrs as needed for pain LORAZEPAM - 0.5 mg tablet - [**1-23**] Tablet(s) by mouth q6hrs as needed for anxiety Do not drive while taking this medication OMEPRAZOLE [PRILOSEC] -  (Prescribed by Other Provider) - 20 mg capsule,delayed release(DR/EC) - 1 Capsule(s) by mouth once a day  -Patient also reports taking hydrochlorothiazide 50 mg prn for swelling.
Hydrocodone-Acetaminophen (5mg-500mg 1 TAB PO Q4-6HR:PRN pain  2.
Omeprazole 20 mg PO DAILY 3.
Capecitabine 500 2 PO BID per Dr. [**Last Name (STitle) 3877**] (2 tablet(s) by mouth twice a day Take [**Hospital1 **] for 14days, then stop for 7days and repeat) 4.
Dexamethasone 8 mg PO Q8H on day 2 and 3 after chemotherapy 5.
Lorazepam 0.5-1 mg PO Q6H:PRN anxiety, nausea   Discharge Disposition: Home  Discharge Diagnosis: Primary: colon cancer  Secondary: Desensitization for serious allergic reaction   Discharge Condition: Mental Status: Clear and coherent.
You were admitted for oxaliplatin treatment and desensitization.
